PTEN and melanoma: To better understand mechanisms underlying therapeutic responses, we assessed their impact upon key signaling nodes from vehicle- and drug-treated melanoma lines – specifically the PTEN-deficient WM266.4 and WM793, and PTEN-proficient A375.